BioWorld Science - Articles

Cancer

Guangzhou Imd Therapeutics presents new BRD2 and GSPT1 degradation inducers

Dec. 11, 2023

Guangzhou Imd Therapeutics Co. Ltd. has divulged proteolysis targeting chimeric (PROTAC) compounds comprising a protein cereblon (CRBN) binding moiety covalently bound to a eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) and/or bromodomain-containing protein 2 (BRD2) targeting moiety through a linker.

Musculoskeletal

Shanghai Meiyue Biotech Development describes new MAPK p38 inhibitors

Dec. 11, 2023

Shanghai Meiyue Biotech Development Co. Ltd. has identified MAPK p38 inhibitors reported to be useful for the treatment of cancer, arthritis, psoriasis, systemic lupus erythematosus, diabetes, atherosclerosis and Alzheimer’s disease.

Immuno-oncology

Simcere Zaiming Pharmaceutical divulges new ADCs targeting CDH6 for cancer

Dec. 11, 2023

Simcere Zaiming Pharmaceutical Co. Ltd. has synthesized antibody-drug conjugates (ADC) comprising humanized monoclonal antibodies targeting CDH6 covalently linked to a camptothecin analogue through a linker.

Cancer

Touchstone Innovations patents new GCN2 inhibitors

Dec. 11, 2023

Touchstone Innovations Ltd. has disclosed eukaryotic translation initiation factor 2-α kinase 4 (GCN2) inhibitors reported to be useful for the treatment of cancer, myocardial ischemia, diabetic cardiopathy, cardiotoxicity, nonalcoholic fatty liver disease and diabetic retinopathy.

Cancer

Dual inhibitor with potentially enhanced safety profile for breast cancer treatment

Dec. 11, 2023

Breast cancer patients receiving aromatase inhibitors as antihormone therapy are at major risk of cardiovascular disease. Previous observations suggest that, since estrogen biosynthesis is regulated by aromatase and aldosterone biosynthesis is modulated by aldosterone synthase, a dual inhibitor could have anticancer efficacy while reducing cardiovascular risks in breast cancer patients.

Neurology/Psychiatric

NX-210c, a promising disease-modifying drug for neurodegenerative disorders

Dec. 11, 2023

Subcommisural organ (SCO)-spondin is a brain-specific glycoprotein essential for neurogenesis with a high impact on neuronal development; thus, reduction in the production of SCO-spondin may lead to a lack of regeneration in neurological disorders.

Neurology/Psychiatric

Selective P2X7 pathway activation enhances skeletal muscle regeneration in ALS mice

Dec. 11, 2023

Previous research has demonstrated that systemic administration of a P2X7 agonist improved motor performance in a mouse model of amyotrophic lateral sclerosis (ALS) through enhancing satellite cells and the muscle pro-regenerative activity of infiltrating macrophages.

Immuno-oncology

Nextpoint obtains IND approval for NPX-887 for HHLA2-expressing solid tumors

Dec. 11, 2023

Nextpoint Therapeutics Inc. has received FDA clearance of its IND application for NPX-887, a fully human monoclonal antibody targeting HHLA2 (B7-H7), a novel immune checkpoint and tumor target antigen highly expressed in many cancers independently of PD-L1.

Immuno-oncology

Vittoria’s VIPER-101 CAR T-cell therapy cleared to enter clinic for T-cell lymphoma

Dec. 11, 2023

Vittoria Biotherapeutics Inc. has received FDA clearance of its IND application to initiate a first-in-human phase I trial with VIPER-101, a gene-edited, autologous, chimeric antigen receptor (CAR) T-cell therapy for treatment of patients with relapsed or refractory T-cell lymphoma.

Neurology/Psychiatric

Discovery of novel mGlu5 receptor NAM with antidepressive activity in mice

Dec. 11, 2023

Researchers from Anhui University presented the discovery and preclinical evaluation of novel negative allosteric modulators (NAMs) of the metabotropic glutamate mGlu5 receptor.